Idiopathic conditions are among the most vexing seen in medicine. Pulmonary Fibrosis is one of the more troublesome diseases in this class. For the final human victim, this insidious mechanism of sickness to progressive fibrosing interstitial lung diseases in its commonest form produces irreversibly scarred lung parenchyma. This invariably impairs patients’ quality-of-life (QoL) and pulmonary function in day-to-day living and lung function overall. And this is the slow path to complete system failure, starting with the lungs. This represents the greatest challenge for the medical community in identifying appropriate therapeutic interventions. A dedicated stem cell clinic, your lungs can be a light guide on the path to recovery alone. The possibility of restoring fibrotic lungs appears as a last-shredded dream for medical researchers long hindered by the antiquated, and occasionally cruelly contrived, medical paradigms of passive lung fibrosis. Care for Patients with Pulmonary Fibrosis should be further focused and customized to restore the cellular imbalances or deficiencies of lung fibrosis.
Essentially, pulmonary fibrosis is the deposition of fibrotic tissue (scar) in the lung parenchyma that follows an abnormal healing response of the alveolar epithelium. Following these injuries, a cascade of pathological processes occurs responsible for fibroblast proliferation. These fibroblasts can then differentiate into myofibroblasts and subsequently lay down abundant collagen-rich fibrotic tissue filling the interstitium. This leads to the destruction of the alveolar capillary bed and the structural changes required to allow for gas exchange at a distance through alveolar interstitium. Prolonged cough with simple lethargy and not tolerating exertion will develop along with respiratory distress. This results in cascades into this fibrotic tissue which makes the lungs a stiff and hard shell. Unfortunately, the fibrotic remodelling of the lungs is essentially a death sentence. This incentivizes those individuals to look for a stem cell clinic.
Figure 1: Pathophysiology of Pulmonary Fibrosis
Traditionally, how Pulmonary Fibrosis is altered is dependent on the chronic use of immunosuppressants and the use of antifibrotic therapy. Pirfenidone and other medications slow lung function decline by affecting fibrogenic biological pathways. Although they alter fibrotic pathways, pirfenidone and other drugs available today have multiple limitations. These drugs don’t reverse the damage done to the tissue and lungs of the patients, nor do they reverse scarring. Additionally, they have significant gastrointestinal and liver side effects. While patients take the medications, if any of these side effects are intolerable, the medications must be discontinued. If all of these drugs become ineffective, the last resort is lung transplantation. Alternative options outside a stem cell clinic are limited by the rapidly growing and serious risk of acute transplant rejection. In sum, this is insufficient treatment. The risk of serious outcomes from the ongoing and primary side effects of this treatment is unjustifiable. Additionally, the need to endure this treatment to the end is unreasonably prevented by the great global organ transplantation risk.
Regenerative medicine has the potential to actually repair tissue damage, and significant progress has been made in this area. There are undeniable benefits of access to cellular therapy in the stem cell clinic. Mesenchymal stem cells have the ability to modulate the lung microenvironment to aid tissue repair. These cells can even reverse and modulate severe fibrotic pathways. Moreover, they can even reverse and modulate pathological tissue changes in the lung microenvironment and repair the damage. These cells can help and even reverse the damage done to the lung microenvironment. Providing treatment to the subject is a premier stem cell treatment clinic. Cellular therapy can even reverse and modulate tissue damage in the lungs of patients with Pulmonary Fibrosis.
Figure 2: A Paradigm shift of Pulmonary Fibrosis treatment
Recently, the focus on advanced therapies based in the association of the three regions centered in the Greater Mekong Subregion has become prominent. Thailand is one of the three regions and is considered the earliest mover (and probably the most accomplished) in establishing a center for the integration of higher medical infrastructures and supervised biological research. In the tropical zone, a globally accredited stem cell clinic is compliant with international standards on safety while using better biomedical technologies. The component of the National Government to subsidize medical innovation promotes a safe realm for cellular therapies to flourish. This, paired with the low cost of health, attracts a lot of medical tourists. Actively treating Pulmonary Fibrosis in this developing medical framework entails providing international patients with elite clinical facilities right at their doorstep. The short-term trend that indigenously embodies the evolving medical framework in Thailand suggests that personalized cellular medicine will very soon respond to the needs of all citizens.
Fatal lung scarring calls for the integration of therapies that go beyond symptom control. Cellular therapies, through their ability to control lung-targeted inflammation, can rejuvenate the lung and control other systemic inflammation. Attending a dedicated stem cell clinic can help those afflicted by a medical condition that is universally regarded as incurable by providing them with additional medical options that can help them combat their condition. Delivering a better prognosis relies on the breakthrough potential that great risks and great rewards possess. Ultimately, a healthier tomorrow depends on a breakthrough in Pulmonary Fibrosis and the pursuit of other living biological tests.